VAL-083 a modern and unique cancer chemotherapy, being developed to treat glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer, and other solid tumor indications.
Our mission is to benefit patients and create shareholder value by rapidly developing and commercializing anti-cancer therapies in orphan cancer indications where patients have failed or are unlikely to respond to modern therapy.
DelMar Pharmaceuticals is a clinical and commercial stage drug development company with a focus on the treatment of cancer. We are conducting clinical trials in the United States with our product candidate, VAL-083, as a potential new treatment for glioblastoma multiforme (GBM).
DelMar Pharmaceuticals to Present Data on the Promising Potential of VAL-083 in the Treatment of Pediatric Brain Tumors
DelMar Pharmaceuticals to Present an Interactive Live Webcast at VirtualInvestorConferences.com on October 1, 2015
DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme at GBM2015
VAL-083, our first product candidate, represents a "first-in-class" small molecule chemotherapeutic, which means that the molecular structure of VAL-083 is not an analogue or derivative of other small molecule chemotherapeutics approved for the treatment of cancer.Learn more about VAL-083
Our mission is to benefit patients and create shareholder value by rapidly developing and commercializing anti-cancer therapies in orphan cancer indications where patients have failed or are unlikely to respond to modern therapy.Learn more about DelMar
Our drug discovery research focuses on identifying well-validated clinical and commercial-stage compounds and establishing a scientific rationale for development in modern orphan drug indications.Learn more about our drug development pipeline